# Semax: Human Brain Imaging, No Cognitive Outcome By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-21 | Updated: 2026-10-30 Canonical page: https://glpwatchdog.org/research/semax-brain-imaging-without-an-outcome > Semax has human data (52 healthy participants, resting-state fMRI, a placebo arm), and it found changes in brain connectivity. It did not measure memory, attention or any task performance. ## Key points - 52 healthy participants, resting-state fMRI before and 5 and 20 minutes after injection of semax, selank or placebo. - Differences were found in functional connectivity involving the right amygdala and temporal regions. - No memory, attention or task performance was measured, and participants had no cognitive deficit to improve. - The mechanistic work is rodent neurochemistry; the evidence base shares its limitations with selank. Semax is sold as a nootropic, and unlike most compounds in that market it has been studied in people. Fifty-two healthy participants were given semax, [selank](https://glpwatchdog.org/peptides/selank) or placebo and had resting-state fMRI three times: before the injection, then five and twenty minutes after it. Differences in functional connectivity were found, involving the right amygdala and temporal regions.[1] What decides its meaning is the endpoint. **The study measured connectivity between brain regions. It did not measure memory, attention, or any task anybody performed.** ## What was actually measured The design is careful. Regions of interest were predefined rather than fished for: the amygdala, central to anxiety regulation, and the dorsolateral prefrontal cortex, central to executive function including working memory, in both hemispheres. There was a placebo arm. Scans were repeated at fixed intervals.[1] The findings were between-group and between-condition differences in functional connectivity between the right amygdala and a region spanning the fusiform, inferior and middle temporal and parahippocampal gyri. Put plainly, the correlation in activity between two parts of the brain changed after injection. > **A change in a brain measurement is not a benefit.** Caffeine changes brain connectivity. So does a loud noise, a bad night’s sleep and being anxious inside a scanner. To know whether a compound helps you think, somebody has to ask you to think and then score it. This study did not, and it was conducted in healthy participants who had no cognitive deficit to improve. ## The rest of the evidence is rodents Semax is an analog of a fragment of ACTH, and the mechanistic work behind it is animal neurochemistry. In rodents, it activates dopaminergic and serotoninergic brain systems.[2] That is a coherent basis for a hypothesis about mood and cognition, but it is animal work and says nothing yet about people. Put the two together and the shape is familiar from across this market: a plausible mechanism in animals, a measurable signal in a human imaging study, and no trial testing whether anyone functions better. The missing study would be an ordinary one: a randomized trial with a cognitive endpoint. > The evidence is rodent neurochemistry and one imaging study. No trial has tested whether anyone functions better. ## The same caveat as its sibling Semax shares its evidence base, and much of its author group, with [selank](https://glpwatchdog.org/research/selank-what-the-russian-trials-show). Both compounds sit almost entirely within one national research literature, produced largely around the institute that developed them, without independent replication elsewhere. The weakness lies in how the evidence is structured, not in which country produced it, and it applies to both. - [Semax](https://glpwatchdog.org/peptides/semax) is not an approved medicine in the United States. Most of it is sold as a research chemical, without identity, purity or dose guarantees. How semax compares with selank under the October 2026 HHS policy is in [Semax vs Selank](https://glpwatchdog.org/research/semax-vs-selank). - Under an interim policy dated October 28, 2026, HHS does not plan to pursue state-licensed 503A pharmacies that compound semax free base as an intranasal product only, on a patient-specific prescription and under strict testing and labeling conditions. The policy's device condition names only an FDA-cleared syringe, so it leaves open which nasal device may be used. It is not an approval, and it does nothing to the evidence described here.[3] - The human study measured brain connectivity in healthy volunteers, with no cognitive or symptom endpoint. - The mechanistic work is in rodents. - If you are seeking help with concentration, memory or mood, have those problems assessed properly. Several have treatable causes, and none of them is diagnosed by a peptide vendor. ## Frequently asked questions ### Does semax improve cognition? No study we found tested that. The human research measured resting-state functional connectivity between brain regions in 52 healthy participants. It did not measure memory, attention or any task performance. A change in a brain measurement is not the same as improved function. ### What is semax? A synthetic analog of a fragment of ACTH, developed in Russia and sold as a nootropic. In rodents it activates dopaminergic and serotoninergic systems, which is the mechanistic basis for interest in it. ### Was the human study any good? As an imaging study, it was well constructed: predefined regions of interest, a placebo arm, and scans repeated at fixed intervals. Its limitation is what it chose to measure, not how it measured it. ### Is semax approved? Not in the United States. Most of it is sold as a research chemical, outside the manufacturing and labeling standards that apply to prescription medicines. Under an interim policy dated October 28, 2026, HHS does not plan to pursue state-licensed 503A pharmacies that compound semax free base as an intranasal product only, as the only active ingredient, on a patient-specific prescription and under strict testing and labeling conditions. That is enforcement discretion, not approval. ## References 1. Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020. PMID: 32342318. https://pubmed.ncbi.nlm.nih.gov/32342318/ 2. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005. PMID: 16362768. https://pubmed.ncbi.nlm.nih.gov/16362768/ 3. U.S. Department of Health and Human Services HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (with Appendices A and B), announced October 28, 2026. HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf --- Cite as: GLP Watchdog, Nora Bissett, "Semax: Human Brain Imaging, No Cognitive Outcome", published 2026-08-21, updated 2026-10-30. https://glpwatchdog.org/research/semax-brain-imaging-without-an-outcome Canonical HTML page: https://glpwatchdog.org/research/semax-brain-imaging-without-an-outcome Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.